Research programme: defensin mimetic therapeutics - Innovation Pharmaceuticals
Alternative Names: Arylamide series - PolyMedix; Bactericidal amphiphilic antibiotic compounds - PolyMedix; Calixarene series - PolyMedix; CTIX 1278; CTX 1807; Defensin-mimetics - PolyMedix; HDP mimetic compounds - Innovation Pharmaceuticals; Human defense protein mimetics - Innovation Pharmaceuticals; Hydrazide series - PolyMedix; PMX 1408; PMX 1502; PMX 196; PMX 225; PMX 231; PMX 243; PMX-10004; PMX-10033; PMX-10036; PMX-10052; PMX-10056; PMX-10065; PMX-10066; PMX-10067; PMX-10068; PMX-10070; PMX-10072; PMX-10098; PMX-30006; PMX-30016; PMX-30024; PMX-40007; PMX-50003; PMX-519; PMX-60006; PMX-60007; PMX-60014; PMX-70004; PMX-70008; Salicylamide series - PolyMedixLatest Information Update: 10 Mar 2023
At a glance
- Originator PolyMedix
- Developer Innovation Pharmaceuticals
- Class Calixarenes; Small molecules
- Mechanism of Action Cell membrane permeability enhancers; Cell membrane structure modulators; Defensin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Acne vulgaris; Anthrax; Gram-negative infections; Hidradenitis suppurativa; Malaria; Mycoses; Proctitis; Rosacea; Tuberculosis
Most Recent Events
- 10 Mar 2023 Discontinued - Preclinical for Anthrax in USA (Intraperitoneal)
- 10 Mar 2023 Discontinued - Preclinical for Hidradenitis suppurativa in USA (Topical)
- 10 Mar 2023 Discontinued - Preclinical for Malaria in USA (unspecified route)